INTRODUCTION
============

Concurrent exercise is the combination of strength and aerobic exercise during the same session or training program ([@b10-jer-13-2-179]), and it has been shown to impair long-term strength development ([@b7-jer-13-2-179]; [@b17-jer-13-2-179]). Studies suggest that the reduction in performance during a session of strength training (i.e., maximum number of repetitions, intensity, or total volume) after aerobic activity, especially high-intensity intermittent exercise ([@b3-jer-13-2-179]; [@b8-jer-13-2-179]), can contribute to a long-term impairment compared to strength training performed solely ([@b1-jer-13-2-179]; [@b10-jer-13-2-179]).

Therefore, strategies for attenuating the decrease of strength performance, such as nutritional supplementation preceding high-intensity endurance exercise, are necessary to preserve the elevated levels of translation initiation and protein synthesis ([@b14-jer-13-2-179]).

Caffeine (CAF) ingestion can delay neuromuscular fatigue and increase performance by acting on the central nervous system ([@b2-jer-13-2-179]). Moreover, it affects K^+^ accumulation in the muscle ([@b12-jer-13-2-179]) and the action of Ca^2+^ in the sarcoplasmic reticulum (SR) ([@b4-jer-13-2-179]). Furthermore, it is known that endurance exercise promotes acute metabolic changes during the subsequent strength exercise sessions, resulting in the depletion of glycogen stores ([@b10-jer-13-2-179]). CAF may improve resistance training performance by inhibiting the glycogen phosphorylase enzymes and attenuating glycogen depletion ([@b11-jer-13-2-179]).

Moreover, CAF accelerates the release of exercise-induced beta-endorphin, epinephrine, cortisol, and increases interleukin-6 (IL-6) levels, and these alterations in the immunoendocrine response contribute to the benefits of CAF on exercise performance ([@b16-jer-13-2-179]; [@b18-jer-13-2-179]).

To the best of our knowledge, there is no data in the literature investigating the effects of CAF and carbohydrate (CHO) intakes on concurrent strength performance. Therefore, the purpose of this study was to examine the effects of CAF and CHO intake on acute strength performance and the immunoendocrine responses during high-intensity intermittent endurance exercise. Our hypothesis is that the consumption of CHO and CAF will reduce skeletal muscle fatigue, improve strength performance and immunoendocrine responses during endurance exercise.

MATERIALS AND METHODS
=====================

Sample and sampling
-------------------

Seven healthy active males (27±3 years, 172.0±0.1 cm, 70.5± 5.3 kg; 1RM half-squat, 152.7±30.8 kg; peak speed in running test, 14.4±1.3 km/hr), habitual CAF users participated in this study. Participants took part in the study voluntarily after being informed of the procedures, risks, and benefits. All participants signed a consent form. This study was approved by the Ethics Committee. Regarding the effect size, the sample size of the present study had an 80% power of detecting differences between groups regarding the maximum number of repetitions.

Design
------

In previous sessions, the participants performed anthropometric measurements, a graded exercise test to assess peak treadmill speed (Vmax) (MASTER CI, Inbramed, Porto Alegre, Brazil), and one-repetition maximum test (1RM) in Smith machine (Ipiranga, Presidente Prudente, Brazil). After that, the subjects performed three randomized, concurrent exercise sessions ([Fig. 1](#f1-jer-13-2-179){ref-type="fig"}).

Concurrent exercise sessions
----------------------------

Participants completed a warm-up at 50% of Vmax for 5 min, and after a 2-min rest interval, the exercise bout was started. The endurance exercise consisted of a 5-km intermittent run on a treadmill, corresponding to 1 min at the Vmax followed by 1 min of passive recovery (1:1 effort and pause ratio). After a 10-min passive rest interval, the subjects performed four sets of half-squat at 80% of 1RM on a Smith machine (Ipiranga). All sets were performed until failure, and each set was separated by a 2-min rest interval. The maximum number of repetitions performed was recorded, and the total volume was calculated (repetitions × weight lifted). All tests took place during the same time of the day for each subject. The subjects were instructed to abstain from any strenuous exercise or CAF ingestion at least 48 hr before each testing session and were encouraged to maintain their nutritional and hydration routines.

CAF, CHO, and P ingestion
-------------------------

The CAF, CHO, and P were ingested according to [Table 1](#t1-jer-13-2-179){ref-type="table"}.

For all three experimental groups, subjects consumed a 300-mL calorie-free flavored (i.e., lemon) beverage (Clight, Nutriguía, Brazil) and ingested two capsules, as follows: P group: subjects ingested the beverage and two cellulose capsules; CAF group: subjects ingested the beverage and 5 mg/kg (control body weight) of pure CAF (Uniformula manipulation pharmacy, Presidente Prudente, Brazil); CHO group: subjects ingested a 20% maltodextrin solution (Athletica Nutrition, ADS Laboratório Nutricional Ltda, Matão, Brazil) diluted in 300 mL of water and two cellulose capsules.

Blood sampling and analyses
---------------------------

Blood samples were collected in P, CHO, and CAF groups. Glucose and lactate were assessed using commercial kits (Labtest, São Paulo, Brazil). Nonester fatty acid (NEFA) was assessed by a colorimetric method with a commercial kit (Wako Diagnostics, 1025 Terra Bella Ave, Suite A Mountain View, CA, USA). Cytokines (IL-6, and tumor necrosis factor \[TNF\]-α) were assessed using ELISA commercial kits (Affymetrix/eBioscience, São Paulo, Brasil).

Statistical analysis
--------------------

The data was analyzed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and presented as mean and standard deviation. Linear mixed models were used to compare the maximum number of repetitions during each set in different groups (group×set), as well as blood variables in different groups over time (group×time). The Tukey *post hoc* was used if significant differences were found. The "mean differences" (postvalues minus prevalues) were calculated and analyzed by one-way analysis of variance. If a significant difference was found, Tukey *post hoc* was used again. The effect size was calculated. Statistical significance was set at *P*\<0.05.

RESULTS
=======

The high-intensity intermittent exercise was concluded in 42.9±4 min. The maximum number of repetitions during each set per groups is presented in [Table 2](#t2-jer-13-2-179){ref-type="table"}. For the maximum number of repetitions, there was a main effect of set (*F*\[3, 66\]=11.7, *P*\<0.001) with higher maximum number of repetitions performed during the first set than during the second set (*P*=0.020), third set (*P*\<0.001) and fourth set (*P*\<0.001).

[Table 3](#t3-jer-13-2-179){ref-type="table"} showed the metabolic variables in P, CAF, and CHO groups.

Regarding glucose, there was a significant interaction (*P*= 0.019, ES=0.48). *Post hoc* analysis found higher values for CHO compared to P postexercise. When compared the delta between condition (postvalues minus prevalues), there was lower values in CAF in relation to CHO (CAF=5.0±10.4 vs. CHO=27.8±20 vs. P=15.1±14, *P*=0.031).

In relation to lactate, there was a main effect of time (*P*\<0.001, ES=0.88) but there was no difference between condition and interaction (*P*\>0.05).

About NEFA, there was no a main effect of time, interaction but there was a trend to difference between condition (*P*=0.060, ES=0.50).

[Table 4](#t4-jer-13-2-179){ref-type="table"} presented the inflammatory variables in P, CAF, and CHO groups.

Regarding IL-6, there was no significant difference between condition but there was significant interaction (*P*=0.024), *post hoc* showed higher IL-6 only for CAF condition postexercise compared to preexercise (*P*=0.039) and trend a main effect of time (*P*=0.064, ES=0.46). When compared the changes between condition again (Δ, [Fig. 2](#f2-jer-13-2-179){ref-type="fig"}), there was higher values in CAF in relation to CHO (CAF=11.9±9.2 vs. CHO= −2.4±1.7 vs. P=4.3± 11.7, *P*=0.017).

In relation to TNF-α, there was no a main effect for condition (*P*=0.065) and interaction (*P*\>0.05) but there was a trend across time (*P*=0.072, ES=0.50).

DISCUSSION
==========

The main finding of the present study was that CAF and CHO intakes did not improve performance in concurrent strength sessions, and CAF consumption led to higher IL-6 level after the concurrent strength exercise.

Despite the energy availability provided by CHO consumption, which sustained high blood glucose levels, strength performance was not decreased. This finding could be explained by the inability or difficulty of muscle cells to uptake and utilize the glucose, which is reinforced by the lack of correlation between glucose and lactate in CHO group compared to the P group, where there was a correlation between the same variables. This possibly explains the lack of increase in lactate concentrations in the CHO group.

An explanation to understand such findings is the exercise protocol used, characterized as high intensity, which produces a metabolic stressful environment. An indication of that is the increase of H^+^ ions, making the cellular environment more acidic. This acidity may adversely affect various mechanisms, such as the reduced SR action that impairs muscle contraction, and phosphofructokinase inhibition, impairing energy metabolism. In agreement, the energy deficit also impairs the action of ATPase in the Na^+^ and K^+^ channels in the plasma membrane and Ca^2+^ channels in SR. Moreover, it seems that Ca^2+^ has a relevant role in glucose transporter 4 (GLUT4) translocation in parallel to AMP protein kinase action during exercise ([@b5-jer-13-2-179]). Accordingly, if Ca^2+^ release and uptake are impaired, there is also impairment of the GLUT4 translocation, thus hindering glucose uptake. However, more studies are needed to elucidate these mechanisms.

Our findings show that CAF intake also did not attenuate fatigue during the concurrent strength exercise. In agreement with our results, [@b15-jer-13-2-179] and [@b9-jer-13-2-179] observed that CAF ingestion (5 mg/kg) had no ergogenic effect on strength performance. However, [@b13-jer-13-2-179] tested the effect of three different doses of CAF (3, 6, and 9 mg/kg) on four progressive loads (25%, 50%, 75%, and 90% 1MR). They found that the three doses were effective in prolonging the time to exhaustion, and 3 mg/kg was sufficient to improve the propulsion speed for lower loads (25% and 50% 1MR), while higher doses (6 and 9 mg/kg, respectively) were required for moderate (75% 1MR) and heavy (90% 1MR ) loads.

Regarding IL-6, we found higher levels immediately after concurrent strength only in the CAF group. Few studies have examined effects of CAF consumption on endurance exercise and immunoendocrine response ([@b16-jer-13-2-179]; [@b18-jer-13-2-179]). However, the cytokines, specifically IL-6 and TNF-α, have been considered an energetic sensor, in a hormone-like manner, that can mobilize extracellular glucose and free fatty acids during exercise ([@b6-jer-13-2-179]). Collectively with our data, this suggests that CAF consumption during concurrent strength training can promote changes in the immunoendocrine response, and also facilitate lipolysis and glycogenolysis to provide energy supply for the skeletal muscle and other tissues during and after exercise. Therefore, CAF can affect the immunometabolic response of concurrent exercise. However, future research is needed to better understanding.

The present study has some limitations. First, the experimental design differs from others because it is a concurrent strength protocol, which consists of high-intensity intermittent endurance exercise performed before strength exercise. Second, although scientific literature claims that peak plasma concentration of CAF may occur between 15 and 120 min after oral ingestion ([@b11-jer-13-2-179]), it is possible that the allotted time for absorption of the CAF before the strength exercise (30 min) was not sufficient. However, more studies are necessary to better understand the mechanisms involved in time-release and effective nutritional supplementation.

In conclusion, CAF and CHO intake did not improve strength performance during concurrent strength exercise in active males but promoted changes in immunometabolic responses.

The São Paulo Research Foundation (FAPESP; 2013/25310-2).

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

![Experimental design.](jer-13-2-179f1){#f1-jer-13-2-179}

![(A) Comparison between placebo, caffeine, and carbohydrate groups on the absolute variation (Δ) after concurrent exercise sessions for glucose (mg/dL). (B) Comparison between placebo, caffeine, and carbohydrate groups on the absolute variation (Δ) after concurrent exercise sessions for interleukin (IL)-6 (pg/mL).](jer-13-2-179f2){#f2-jer-13-2-179}

###### 

Caffeine, carbohydrate, and placebo ingestion

  Placebo                                      Caffeine                                    Carbohydrate
  -------------------------------------------- ------------------------------------------- -----------------------------------
  Calorie-free flavored beverage + cellulose   Calorie-free flavored beverage + caffeine   Maltodextrin solution + cellulose

Calorie-free flavored beverage (300 mL), carbohydrate 20% (300 mL), Caffeine (5 mg/kg), or celulose (2 capsules).

###### 

The maximum number of repetitions and total volume performed (kg) in placebo, caffeine, and maltodextrin group

  Variable                                             Placebo           Caffeine                                                                                           Carbohydrate
  ---------------------------------------------------- ----------------- -------------------------------------------------------------------------------------------------- -----------------
  Set 1                                                17.0±8.2          14.6±5.3                                                                                           13.9±7.4
  Set 2[\*](#tfn4-jer-13-2-179){ref-type="table-fn"}   11.6±3.8          11.8±2.3                                                                                           11.4±6.0
  Set 3[\*](#tfn4-jer-13-2-179){ref-type="table-fn"}   9.3±2.8           10.7±2.7                                                                                           9.7±4.8
  Set 4[\*](#tfn4-jer-13-2-179){ref-type="table-fn"}   8.6±3.0           7.1±2.5[†](#tfn5-jer-13-2-179){ref-type="table-fn"},[‡](#tfn6-jer-13-2-179){ref-type="table-fn"}   9.8±6.3
  MNR                                                  46.4±14.8         44.3±6.8                                                                                           44.9±23.4
  Total volume                                         5,631.9±2,245.8   5,413.1±1,387.5                                                                                    5,616.1±3,189.7

Values are presented as mean±standard deviation.

MNR, maximal number of repetition.

Tukey *post hoc* test with *P*-value \<0.05 compared to set 1.

Tukey *post hoc* test with *P*-value \<0.05 compared to set 2

Tukey *post hoc* test with *P*-value \<0.05 compared to set 3.

###### 

Metabolic variables in placebo, caffeine, and carbohydrate groups

  Variable           Placebo      CV (%)   Caffeine    CV (%)   Carbohydrate                                              CV (%)
  ------------------ ------------ -------- ----------- -------- --------------------------------------------------------- --------
  Glucose (mg/dL)                                                                                                         
   Pre               94.8±7.8     2.8      93.8±7.7    1.8      101.9±12.1                                                2.9
   Post              109.9±15.1   5.8      98.8±10.5   1.9      129.7±10.7[\*](#tfn9-jer-13-2-179){ref-type="table-fn"}   6.2
                                                                                                                          
  Lactate (mmol/L)                                                                                                        
   Pre               1.2±0.3      2.3      1.3±0.4     5.9      1.5±0.1                                                   2.8
   Post              6.2±1.8      3.5      6.8±2.7     2.4      6.4±2.3                                                   3.2
                                                                                                                          
  NEFA (mmol/L)                                                                                                           
   Pre               0.50±0.1     4.1      0.70±0.2    7.0      0.73±0.1                                                  7.1
   Post              0.54±0.1     1.4      0.70±0.2    4.4      0.80±0.1                                                  8.3

Values are presented as mean±standard deviation.

CV, coefficient of variation; NEFA, nonesterified fatty acids.

Statistically significant difference between placebo and carbohydrate groups.

###### 

Inflammatory variables in placebo, caffeine, and carbohydrate groups

  Variable        Placebo    Caffeine                                                  Carbohydrate
  --------------- ---------- --------------------------------------------------------- --------------
  IL-6 (pg/mL)                                                                         
   Pre            18.5±9.0   16.9±6.5                                                  21.7±6.7
   Post           22.8±7.2   28.8±12.1[\*](#tfn12-jer-13-2-179){ref-type="table-fn"}   19.4±6.7
                                                                                       
  TNF-α (pg/mL)                                                                        
   Pre            9.7±7.66   11.2±3.6                                                  10.6±3.6
   Post           11.1±3.5   13.4±5.6                                                  11.9±3.2

Values are presented as mean±standard deviation.

IL, interleukin; TNF, tumor necrosis factor.

Statistically significant difference between caffeine and carbohydrate groups.
